by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Amyloid beta (Aβ) plaques and hyperphosphorylated tau in the entorhinal regions are key Alzheimer’s disease (AD) markers, but the spatial Aβ pathways influencing tau pathology remain unclear. METHODS We applied predictive modeling to...
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Plasma-based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer’s disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated....
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract INTRODUCTION Plaques are a hallmark feature of Alzheimer’s disease (AD). We found that the loss of mucosal-associated invariant T (MAIT) cells and their antigen-presenting molecule MR1 caused a delay in plaque pathology development in AD mouse models....
by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia
Abstract Aging rhesus macaques provide a unique model for learning how age and inflammation drive early-stage pathology in sporadic Alzheimer’s disease, and for testing potential therapeutics. Unlike mice, aging macaques have extensive association cortices and...
by Clinical Neuropsychologist | Tuesday, January 7, 2025 | Dementia
Abstract INTRODUCTION Cerebrovascular pathologic changes (CVPC) are prevalent and associated with dementia in those ≥ 90 years. However, CVPC associations to traditional risk factors (hypertension, diabetes, and hyperlipidemia) are variable. We hypothesized that...
by Clinical Neuropsychologist | Monday, January 6, 2025 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Ozioma C. Okonkwo, Monica Rivera‐Mindt, Michael W. Weiner, for...
